Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs

Journal of Medicinal Chemistry

Volumn 51, Issue 22, 2008, Pages 7075-7093

  Boyer, Serge H ^a   Jiang, Hongjian ^a   Jacintho, Jason D ^a   Reddy, Mali Venkat ^a   Li, Haiqing ^a   Li, Wenyu ^a   Godwin, Jennifer L ^a   Schulz, William G ^a   Cable, Edward E ^a   Hou, Jinzhao ^a   Wu, Rongrong ^a   Fujitaki, James M ^a   Hecker, Scott J ^a   Erion, Mark D ^a  

^a Metabasis Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(3,5 DIMETHYL 4 (4' HYDROXY 3' ISOPROPYLBENZYL)PHENOXY)METHYL] 4 (3 CHLOROPHENYL) 2 OXIDO[1,3,2]DIOXA PHOSPHONANE; 2 [3,5 DIBROMO 4 (4' HYDROXY 3' ISOPROPYLPHENOXY)PHENYL]ETHYLPHOSPHONIC ACID; 3,5 DIIODO 4 (4' HYDROXY 3' ISOPROPYLPHENOXY)BENZYLPHOSPHONIC ACID; [3,5 DIBROMO 4 (4' HYDROXY 3' ISOPROPYLPHENOXY)PHENOXY]METHYLPHOSPHONIC ACID; [3,5 DIBROMO 4 (4' HYDROXY 3' ISOPROPYLPHENOXY)PHENYLAMINO]METHYLPHOSPHONIC ACID; [3,5 DIMETHYL 4 (3' ETHYL 4' HYDROXYBENZYL)PHENOXY]METHYLPHOSPHONIC ACID; [3,5 DIMETHYL 4 (3' SEC BUTYL 4' HYDROXYBENZYL)PHENOXY]METHYLPHOSPHONIC ACID; [3,5 DIMETHYL 4 (4'HYDROXY 3' ISOPROPYLBENZYL)PHENOXY]METHYLPHOSPHONIC ACID; [4 (4' HYDROXY 3' ISOPROPYLBENZYL) 3,5 DIMETHYLPHENYLAMINO]METHYLPHOSPHONIC ACID; CARBOXYLIC ACID DERIVATIVE; CHOLESTEROL; GLYCEROL 3 PHOSPHATE DEHYDROGENASE; LIPID; MB 07811; PHOSPHONIC ACID DERIVATIVE; PRODRUG; THYROID HORMONE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASSAY; BINDING AFFINITY; BIOLOGY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFECT; ENZYME ACTIVITY; FEEDING; HEART; HUMAN; HYPERCHOLESTEROLEMIA; LIVER; MITOCHONDRION; NONHUMAN; RAT; SCREENING; SYNTHESIS;

ANIMALS; CHOLESTEROL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GLYCEROLPHOSPHATE DEHYDROGENASE; HYPERCHOLESTEROLEMIA; LIGANDS; LIVER; MOLECULAR STRUCTURE; PHOSPHONIC ACIDS; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, THYROID HORMONE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 56749149595     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800824d     Document Type: Article

References (71)

1. (a) Gardner, C. D.; Fortmann, S. P.; Krauss, R. M. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA, J. Am. Med. Assoc. 1996, 276, 875-881.
2. (b) Stampfer, M. J.; Krauss, R. M.; Ma, J.; Blanche, P. J.; Holl, L. G.; Sacks, F. M.; Hennekens, C. H. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. J. Am. Med. Assoc. 1996, 276, 882-888.
3. (c) Lamarche, B.; Tchernof, A.; Moorjani, S.; Cantin, B.; Dagenais, G. R.; Lupien, P. J.; Despres, J. P. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997, 95, 69-75.
4. Hoyert, D. L.; Heron, M. P.; Murphy, S. L.; Kung, H. Deaths: Final Data for 2003; National Vital Statistics Reports, Vol. 54, No. 13; National Center for Health Statistics: Hyattsville, MD, 2006.
5. Grundy, S. M.; Cleeman, J. I.; Bairey Merz, C. N.; Brewer, H. B., Jr.; Clark, L. T.; Hunninghake, D. B.; Pasternak, R. C.; Smith, S. C., Jr.; Stone, N. J. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004, 110, 227-239.
6. Metha, J. L., Ed.; Statins: Understanding Clinical Use; Saunders: Philadelphia, PA, 2004.
7. Clader, J. W. The discovery of ezetimibe: a view from outside the receptor. J. Med. Chem. 2004, 47, 1-9.
8. Mandeville, W. H.; Goldberg, D. I. The sequestration of bile acids, a non-absorbed method for cholesterol reduction. A review. Curr. Pharm. Des. 1997, 3, 15-28.
9. (a) Pederson, T. R.; Olsson, A. G.; Faergeman, O.; Kjekshus, J.; Wedel, H.; Berg, K.; Wilhelmsen, L.; Haghfelt, T.; Thorgeirsson, G.; Pyorala, K.; Miettinen, T.; Christophersen, B.; Tobert, J. A.; Musliner, T. A.; Cook, T. J. Lipoprotein changes and reduction in the incidence of major coronary heart disease in the Scandanavian simvistatin survival study (4S). Circulation 1998, 97, 1453-1460.
10. (b) The West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland coronary prevention study (WOSCOPS). Circulation 1998, 97, 1440-1445.
11. (a) Knopp, R. H. Drug treatment of lipid disorders. N. Engl. J. Med. 1999, 34, 498-511.
12. (b) Grundy, S. M. Statin trials and goals of cholesterol-lowering therapy. Circulation 1998, 97, 1436-1439.
13. Lazar, M. A. Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr. Rev. 1993, 14, 184-193.
14. Yen, P. M. Physiological and molecular basis of thyroid hormone action. Physiol. Rev. 2001, 81, 1097-1142.
15. 1-deficient mice is an intrinsic defect. Am. J. Phys. 1998, 275 (2, Part 2), R640-R646.
16. 1. EMBO J. 1998, 17, 455-461.
17. (a) Kahaly, G. J.; Matthews, C. H.; Mohr-Kahaly, S.; Richards, C. A.; Chatterjee, V. K. K. Cardiac involvement in thyroid hormone resistance. J. Clin. Endocrinol. Metab. 2002, 87, 204-212.
18. (b) Refetoff, S.; Weiss, R. E.; Usala, S. J. The syndromes of resistance to thyroid hormone. Endocr. Rev. 1993, 14, 348-399.
19. (a) Boyd, G. S.; Oliver, M. F. The effect of certain thyroxine analogues on the serum lipids in human subjects. J. Endocrinol. 1960, 21, 33-43.
20. (b) Ballantyne, F. C.; Epenetos, A. A.; Caslake, M.; Forsythe, S.; Ballantyne, D. The composition of low-density lipoprotein and very-low-density lipoprotein subfractions in primary hypothyroidism and the effect of hormone-replacement therapy. Clin. Sci. (London) 1979, 57, 83-88.
21. (c) Hansson, P.; Valdemarsson, S.; Nilssonehle, P. Experimental hyperthyroidism in man: effects on plasma-lipoproteins, lipoprotein-lipase and hepatic lipase. Horm. Metab. Res. 1983, 15, 449-452.
22. (a) Gomberg-Maitland, M.; Frishman, W. H. Thyroid hormone and cardiovascular disease. Am. Heart J. 1998, 135, 187-196.
23. (b) Klein, I.; Ojamaa, K. Mechanisms of disease: thyroid hormone and the cardiovascular system. N. Engl. J. Med 2001, 344, 501-509.
24. Baxter, J. D.; Dillman, W. H.; West, B. L.; Huber, R.; Furlow, J. D.; Fletterick, R. J.; Webb, P.; Apriletti, J. W.; Scanlan, T. S. Selective modulation of thyroid hormone receptor action. J. Steroid Biochem. Mol. Biol. 2001, 76, 31-42.
25. Yokoyama, N.; Walker, G. N.; Main, A. J.; Stanton, J. L.; Morrissey, M. M.; Boehm, C.; Engle, A.; Neubert, A. D.; Wasvary, J. M.; Stephan, Z. F.; Steele, R. E. Synthesis and structure-activity relationships of oxamic acid and acetic acid derivatives related to L-thyronine. J. Med. Chem. 1995, 38, 695-707.
26. Taylor, A. H.; Stefan, Z. F.; Steele, R. E.; Wong, N. C. W. Beneficial effects of a novel thyromimetic on lipoprotein metabolism. Mol. Pharmacol. 1997, 52, 542-547.
27. Chiellini, G.; Apriletti, J. W.; Yoshihara, H. A. I.; Baxter, J. D.; Ribeiro, R. C. J.; Scanlan, T. S. A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem. Biol. 1998, 5 (6), 299-306.
28. Grover, G. J.; Egan, D. M.; Sleph, P. G.; Beehler, B. C.; Chiellini, G.; Nguyen, N.-H.; Baxter, J. D.; Scanlan, T. S. Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective action relative to 3,5,3′-triido-L-tyronine. Endocrinology 2004, 145, 1656-1661.
29. Trost, S. U.; Swanson, E.; Gloss, B.; Wang-Iverson, D. B.; Zhang, H.; Volodarsky, T.; Grover, G. J.; Baxter, J. D.; Chiellini, G.; Scanlan, T. S.; Dillman, W. H. The thyroid hormone receptor-β-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology 2000, 141, 3057-64.
30. 1. J. Med. Chem. 2003, 46, 1580-1588.
31. Grover, G. J.; Mellström, K.; Malm, J.; Li, Y.-L.; Bladh, L.-G.; Sleph, P. G.; Smith, M. A.; George, R.; Vennström, B.; Mookhtiar, K.; Horvath, R.; Speelman, J.; Egan, D.; Baxter, J. D. Selective thyroid hormone receptor-β activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 10067-10072.
32. Lin, V. H.; Klepp, H. M.; Hanley, R. M.Sobetirome Is a TRβ-and Liver-Selective Thyromimetic That Can Effect Substantial LDL-C Lowering without Significant Changes in Heart Rate or the Thyroid Axis in Euthyroid Men. Presented at the Endocrine Society Meeting, San Francisco, CA, June 2008; OR36-3.
33. Berkenstam, A.; Kristensen, J.; Mellström, K.; Carlsson, B.; Malm, J.; Rehnmark, S.; Garg, N.; Anderson, C. M.; Rudling, M.; Sjöberg, F.; Angelin, B.; Baxter, J. D. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 663-667.
34. Scanlan, T. S.; Yoshihara, H. A.; Nguyen, N.-H.; Chiellini, G. Selective thyromimetics: tissue-selective thyroid hormone analogs. Curr. Opin. Drug Discovery Dev. 2001, 4, 614-622.
35. Sun, W.; Wu, R.; VanPoelje, P. D.; Erion, M. Isolation of a family of organic anion transporters from human liver and kidney. Biochem. Biophy. Res. Commun. 2001, 283, 417-422.
36. 450 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. J. Am. Chem. Soc. 2004, 126, 5154-5163.
37. Erion, M. D.; Cable, E. E.; Ito, B.; Jiang, H.; Fujitaki, J. M.; Finn, P. D.; Zhang, B.-H.; Hou, J.; Boyer, S. H.; van Poelje, P. D.; Linemeyer, D. L. Targeting thyroid hormone receptor-β agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 15490-15495.
38. Hecker, S. J.; Erion, M. D. Prodrugs of phosphates and phosphonates. J. Med Chem. 2008, 51, 2328-2345.
39. Farquhar, D.; Srivastva, D. N.; Kattesch, N. J.; Saunders, P. P. Biologically reversible phosphate-protective groups. J. Pharm. Sci. 1983, 72, 324-325.
40. Arimilli, M. N.; Kim, C. U.; Dougherty, J.; Mulato, A.; Oliyai, R.; Shaw, J. P.; Cundy, K. C.; Bischofberger, N. Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) prodrugs. Antiviral Chem. Chemother. 1997, 8, 557-564.
41. Périgaud, C.; Gosselin, G.; Lefebvre, I.; Girardet, J.-L.; Benzaria, S.; Barber, I.; Imbach, J.-L. Rational design for cytosolic delivery of nucleoside monophosphates: "SATE" and "DTE" as enzyme labile transient phosphate protecting groups. Bioorg. Med. Chem. Lett. 1993, 3, 2521-2526.
42. De Lombaert, S.; Erion, M. D.; Tan, J.; Blanchard, L.; El-Cheharbi, L.; Ghai, R. D.; Sakane, Y.; Berry, C.; Trapani, A. J. N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidases (NEP, EC 3.4.24.11) inhibitors. J. Med. Chem. 1994, 37, 498-511.
43. Dang, Q.; Kasibhatla, S. R.; Reddy, K. R.; Jiang, T.; Reddy, M. R.; Potter, S. C.; Fujitaki, J. M.; Poelje, P. D. v.; Huang, J.; Lipscomb, W. N.; Erion, M. D. Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes. J. Am. Chem. Soc. 2007, 129, 15480-15490.
44. Michaelis, A.; Kaehne, R. The reaction of alkyl iodides with phosphites. Chem. Ber. 1898, 31, 1048-1055.
45. Sekine, M.; Yamagata, H.; Hata, T. A general convenient method for the synthesis of unesterified carbamoyl and thiocarbamoyl-phosphonic acids. Tetrahedron Lett. 1979, 32, 3013-3016.
46. 4 in the presence of transition metal compounds. Tetrahedron Lett. 1996, 37, 407-410.
47. Berlin, K. D.; Taylor, H. A. The reactions of aroyl halides with phosphates. Esters of aroylphosphonic acids. J. Am. Chem. Soc. 1964, 86, 3862-3866.
48. Chiellini, G.; Nguyen, N.-H.; Yoshihara, H. A. I.; Scanlan, T. S. Improved synthesis of the iodine-free thyromimetic GC-1. Bioorg. Med. Chem. Lett. 2000, 10, 2607-2611.
49. Jorgensen, E. C. Thyroid hormones and analogues. II. Structure-Activity Relationships. Hormonal Proteins and Peptides; Li, C. H., Ed.; Academic Press: New York: 1978; Vol. 6, pp 107-204.
50. Shioiri, T.; Ninomiya, K.; Yamada, S. Diphenylphosphoryl azide. New convient reagent for a modified Curtius reaction and for peptide synthesis. J. Am. Chem. Soc. 1972, 94, 6203-6205.
51. Sun, C.; Bittman, R. An efficient preparation of isosteric phosphonate analogues of sphingolipids by opening of oxirane and cyclic sulfamide intermediates with α-lithiated alkylphosphonic esters. J. Org. Chem. 2004, 69, 7694-7699.
52. Chow, H.; Mak, C. C. Dendritic bis(oxazoline)copper(II) catalysts. 2. Synthesis, reactivity, and substrate selectivity. J. Org. Chem. 1997, 62, 5116-5127.
53. Hudgens, T.; Turnbull, K. D. C-Methylation of phenols, tyrosine derivatives, and a tyrosine-containing peptide. Tetrahedron Lett. 1999, 40, 2719-2722.
54. Evans, D. A.; Katz, J. L.; West, T. R. Synthesis of diaryl ethers through the copper-promoted arylation of phenols with arylboronic acids. An expedient synthesis of thyroxine. Tetrahedron Lett. 1998, 39, 2937-2940.
55. Schlosser, M.; Geneste, H. The organometallic route to benzylamine type monoamine oxidase inhibitors. Tetrahedron Lett. 1998, 54, 10119-10124.
56. Blumenkopf, T. A. An efficient preparation of diethyl phenylsulfonylmethylphosphonate. Synth. Commun. 1986, 16, 139-147.
57. Srivastva, D. N.; Farquhar, D. Bioreversible phosphate protective groups: synthesis and stability of model acyloxymethyl phosphates. Bioorg. Chem. 1984, 12, 118-29.
58. Reddy, R. K.; Matelich, M. C.; Ugarkar, B. G.; Gómez-Galeno, J. E.; DaRe, J.; Ollis, K.; Sun, Z.; Craigo, W.; Colby, T. J.; Fujitaki, J. M.; Boyer, S. H.; van Poelje, P. D.; Erion, M. D. Pradefovir: a liver-targeted prodrug of adefovir for hepatitis B therapy. J. Med. Chem. 2008, 51, 666-676.
59. Stanton, J. L.; Cahill, E.; Dotson, R.; Tan, J.; Tomaselli, H. C.; Wasvary, J. M.; Stephen, Z. F.; Steele, R. Synthesis and biological activity of phenoxyphenyl oxamic acid derivatives related to L-thyronine. Bioorg. Med Chem. Lett. 2000, 10, 1661-1663.
60. Leeson, P. D.; Ellis, D. E.; Emmett, J. C.; Shah, V. P.; Showell, G. A.; Underwood, A. H. Thyroid hormone analogues. Synthesis of 3′-substituted 3,5-diiodo-L-thyronines and quantitative structure-activity studies of in vitro and in vivo thyromimetic activities in rat liver and heart. J. Med. Chem. 1988, 31, 37-54.
61. Haning, H.; Woltering, M.; Mueller, U.; Schmidt, G.; Schmeck, C.; Voehringer, V.; Kretschmer, A.; Pernerstorfer, J. Novel heterocyclic thyromimetics. Bioorg. Med. Chem. Lett. 2005, 15, 1835-1840.
62. Yoshihara, H. A. I.; Apriletti, J. W.; Baxter, J. D.; Scanlan, T. S. Structural determinants of selective thyromimetics. J. Med. Chem. 2003, 46, 3152-3161.
63. Taylor, V. J.; Ragan, C. I. The induction of mitochondrial L-3-glycerolphosphate dehydrogenase by thyroid hormone. Biochim. Biophys. Acta 1986, 851, 46-49.
64. Weitzel, J. M.; Kutz, S.; Radtke, C.; Grott, S.; Seitz, H. J. Hormonal regulation of multiple promoters of the rat mitochondrial glycerol-3-phosphate dehydrogenase gene. Eur. J. Biochem. 2001, 268, 4095-4103.
65. Amos, G.; Kerr, D.; Sernia, C.; Brown, L. β-Adrenoceptor antagonism and the hyperthyroid rat heart. J. Cardiovasc Pharmacol. 1994, 24, 336-343.
66. Boyer, S. H.; Sun, Z.; Jiang, H.; Esterbrook, J.; Gómez-Galeno, J. E.; Craigo, W.; Reddy, K. R.; Ugarkar, B. G.; MacKenna, D. A.; Erion, M. D. Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-β-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma. J. Med. Chem. 2006, 49, 7711-7720.
67. (a) Lee, K. S.; Lim, S. G.; Chuang, W. L.; Hwang, S. G.; Cho, M.; Lai, M. Y.; Chao, Y. C.; Chang, T.-T.; Han, K. H.; Lee, C. M.; Um, S. H.; Yeon, J. E.; Yang, S. S.; Teo, E. K.; Peng, C. Y.; Lin, H. H.; Yang, S. S.; Huo, T. I.; Nguyen, T.; Chen, T. Y.; Hu, K. Q.; Xu, Y.; Sullivan-Bólyai, J. Z. Safety, tolerability, and antiviral activity of pradefovir mesylate in patients with chronic hepatitis B virus infection: 48-week analysis of a phase 2 study. 41st Annual Meeting of the European Association for the Study of the Liver, April 26-30 2006, Vienna, Austria. J. Hepatol. 2006, 44 (S2), S274.
68. (b) Lin, C.-C.; Xu, C.; Teng, A.; Yeh, L.-T.; Peterson, J. Pharmacokinetics of pradefovir and PMEA in healthy volunteers after oral dosing of pradefovir. J. Clin. Pharmacol. 2005, 45 (11), 1250-1258.
69. (c) Erion, M. D.; Bullough, D. A.; Lin, C.-C.; Hong, Z. HepDirect prodrugs for targeting nucleotide-based antiviral drugs to the liver. Curr. Opin. Invest. Drugs 2006, 7, 109-117.
70. Cable, E. E.; Isom, H. C. Metabolism of 3,5,5-trimethylhexanoyl-ferrocene by rat liver: release of iron from 3,5,5-trimethylhexanoyl-ferrocene by a microsomal, phenobarbital-inducible cytochrome P450. Drug. Metab. Dispos. 1999, 27, 255-260.
71. Garrib, A.; McMurray, W. C. A sensitive, continuous spectrophotometric method for assaying α-glycerophosphate dehydrogenase: activation by menadione. Anal. Biochem. 1984, 139, 319-321.